Attached files
file | filename |
---|---|
8-K - FORM 8-K - Protalix BioTherapeutics, Inc. | y04801e8vk.htm |
Exhibit 99.1
Protalix BioTherapeutics to Present at the Bio-Manguinhos International Symposium on
Immunobiologicals in Brazil and the 2011 ILSI-Biomed Conference in Israel
CARMIEL, Israel, April 27, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX,
TASE:PLX), announced today that Dr. David Aviezer, the Companys Chief Executive Officer, will
present at two conferences during May 2011: the Bio-Manguinhos International Symposium on
Immunobiologicals in Brazil and the ILSI-Biomed 2011 Conference in Israel.
Details regarding the conferences are as follows:
Bio-Manguinhos International Symposium on Immunobiologicals
Oral presentation during the session titled, Technological Platform for Biopharmaceutical Production, Wednesday, May 4, 2011 between 3:40PM 4:20PM BRT
Hotel Windsor Barra da Tijuca, Rio de Janeiro, Brazil
Oral presentation during the session titled, Technological Platform for Biopharmaceutical Production, Wednesday, May 4, 2011 between 3:40PM 4:20PM BRT
Hotel Windsor Barra da Tijuca, Rio de Janeiro, Brazil
ILSI-Biomed 2011 Conference
Corporate presentation, Monday, May 23, 2011 between 12:10PM 2:10PM IDT
David InterContinental Hotel, Tel-Aviv, Israel
Corporate presentation, Monday, May 23, 2011 between 12:10PM 2:10PM IDT
David InterContinental Hotel, Tel-Aviv, Israel
Bio-Manguinhos is the technical-scientific unit of the Oswaldo Cruz Foundation (Fiocruz), a
central agency of the Ministry of Health of Brazil. Fiocruz produces and develops
immunobiological items to respond to public health demands. The International Symposium is
structured to cover four thematic areas: vaccines, biotherapeutics, kits for laboratory diagnosis
and regulation.
The ILSI-Biomed 2011 Conference brings together industry leaders to discuss key topics in the
life sciences field, with an emphasis on high-tech innovations within Israel. Over 6,000
attendees from around the world, in the fields of industry, medicine and finance are expected to
attend.
About Protalix
Protalix is a biopharmaceutical company focused on the development and commercialization of
recombinant therapeutic proteins expressed through its proprietary plant cell based expression
system, ProCellEx. Protalixs unique expression system presents a proprietary method for
developing recombinant proteins in a cost-effective, industrial-scale manner in an environment free
of mammalian components and viruses. Protalixs lead compound, taliglucerase alfa, an enzyme
replacement therapy for the treatment of Gaucher disease, completed Phase III development. To
date, marketing applications have been submitted for taliglucerase alfa in the United States,
European Union, Brazil and Israel. Protalixs development pipeline also includes: PRX-105, a
pegylated recombinant human acetylcholinesterase in development for several therapeutic and
prophylactic indications, a biodefense program and an organophosphate-based pesticide treatment
program; PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment
of Fabry disease; an orally-delivered glucocerebrosidase enzyme that is naturally encased in carrot
cells, also for the treatment of Gaucher
disease; and pr-antiTNF, a similar plant cell version of etanercept (Enbrel) for the treatment of
rheumatoid arthritis.
Forward Looking Statements
To the extent that statements in this press release are not strictly historical, all such
statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and
unknown risks and uncertainties that may cause actual future experience and results to differ
materially from the statements made. These statements are based on our current beliefs and
expectations as to such future outcomes. Drug discovery and development involve a high degree of
risk. Factors that might cause material differences include, among others, risks relating to: the
successful preclinical development of our product candidates; the completion of our clinical
trials; the review process of the U.S. Food and Drug Administration, or FDA, the European Medicines
Agency, or EMEA, other foreign regulatory bodies and other governmental regulatory bodies; delays
in the FDAs, the EMEAs or other health regulatory authorities approval of any applications we
file or refusals to approve such filings; the risk that the FDA may find that the information we
provide in a resubmission of the NDA for taliglucerase alfa in response to our receipt of a
complete response letter from the FDA in February 2011 is insufficient for regulatory approval; and
other factors described in our filings with the Securities and Exchange Commission. Companies in
the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or
late-stage clinical trials, even after obtaining promising earlier trial results or in preliminary
findings for such clinical trials. Failure to obtain approval from the FDA, EMEA or any other
foreign regulatory authority of any of our drug candidates in a timely manner, if at all, will
severely undermine our business and results of operations by reducing our potential marketable
products and our ability to generate corresponding product revenues. The statements in this release
are valid only as of the date hereof and we disclaim any obligation to update this information.
Investor Contact
Marcy Nanus
The Trout Group, LLC
Telephone: 646-378-2927
Email: mnanus@troutgroup.com
The Trout Group, LLC
Telephone: 646-378-2927
Email: mnanus@troutgroup.com